<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03283826</url>
  </required_header>
  <id_info>
    <org_study_id>ATA188-MS-101</org_study_id>
    <nct_id>NCT03283826</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis</brief_title>
  <acronym>EMBOLD</acronym>
  <official_title>A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atara Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atara Biotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of ATA188 as a&#xD;
      monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as&#xD;
      monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability,&#xD;
      as assessed by sustained Expanded Disability Status Scale (EDSS) improvement at 12 months in&#xD;
      Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive&#xD;
      multiple sclerosis [PPMS] and secondary progressive multiple sclerosis [SPMS]).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, 2 part study in adult participants with progressive forms of MS&#xD;
      (PPMS/SPMS) with an open-label, single-arm, sequential dose-escalation period (Part 1) and a&#xD;
      double-blind, randomized, placebo-controlled dose-expansion period (Part 2) and open-label&#xD;
      extension (OLE) period. Part 2 and the OLE have been initiated by the sponsor's discretion&#xD;
      based on a review of data from the dose-escalation cohorts.&#xD;
&#xD;
      This study will evaluate the safety and efficacy of ATA188 administered by intravenous (IV)&#xD;
      infusion. ATA188 will be selected for each participant based on matching at least 2 human&#xD;
      leukocyte antigen (HLA) alleles shared between ATA188 and the participant including at least&#xD;
      1 HLA-restricting allele.&#xD;
&#xD;
      In Part 1, participants received 2 cycles of ATA188 and entered 12 months follow-up period&#xD;
      after the last dose of ATA188. Participants who completed at least the first year of the&#xD;
      dose-escalation period and were active in the study have entered in OLE period. In OLE&#xD;
      period, participants will receive the same RP2D assigned to Part 2 participants at the time&#xD;
      of the Part 1 participant's first dose in each year of the OLE. In OLE period, participants&#xD;
      will receive 1 cycle of ATA188 treatment every 12 months (Q12M) for up to 4 years (ie, Years&#xD;
      2 to 5). Otherwise, end of study (EOS) visit will be conducted at 24 months after Cycle 1 Day&#xD;
      1.&#xD;
&#xD;
      In Part 2, participants will be randomized in 1:1 ratio to receive ATA188 at the RP2D or&#xD;
      matching placebo, stratified by progressive MS diagnosis (PPMS vs SPMS) and any prior&#xD;
      exposure to anti-CD20 therapy (yes vs no). Initially 80 participants will be randomized to&#xD;
      ATA188 or placebo. Randomization of additional participants into the study will be based on&#xD;
      the results of the interim analysis. Participants will receive 2 cycles of ATA188 at the RP2D&#xD;
      or matching placebo and will be followed for at least 12 months after the first dose of study&#xD;
      drug (ie, Year 1). In second year (Year 2), participants who received placebo in Year 1 will&#xD;
      receive 2 cycles of ATA188 at the RP2D assigned at randomization and participants who&#xD;
      received ATA188 at the RP2D in Year 1 will receive 1 cycle of ATA188 (at the RP2D assigned at&#xD;
      randomization) and 1 cycle of placebo to maintain the blind. Participants who complete Year 2&#xD;
      will enter in OLE period to receive ATA188 Q12M for up to 3 years (ie, Years 3 to 5) at the&#xD;
      RP2D that was last selected by the sponsor for Part 2. The end of study visit will be&#xD;
      scheduled at 5 years (60 months) after the first dose of study drug (ie, Cycle 1 Day 1).&#xD;
&#xD;
      Part 1 of the study recruitment has completed, Part 2 continues to recruit participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2017</start_date>
  <completion_date type="Anticipated">February 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Incidence of adverse events</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Incidence of clinically significant changes in laboratory tests, electrocardiograms (ECGs), and vital signs</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Recommended Part 2 dose of ATA188 monotherapy</measure>
    <time_frame>Day 1 to Day 35 of Cycle 1 for each participant in dose escalation part (approximately 1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Percentage of participants with sustained expanded disability status scale (EDSS) improvement at 12 months</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change from baseline in EDSS score</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of participants with sustained EDSS improvement at 15 months</measure>
    <time_frame>At 15 months after the first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of participants with sustained disability improvement (SDI) at 12 months</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Percentage of participants with SDI at 15 months</measure>
    <time_frame>At 15 months after the first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from baseline in immunoglobulin G (IgG) index</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from baseline in quantification of IgG production</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline in cervical spinal cord volume on MRI scans</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in whole brain volume on MRI scans</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change from baseline in number of Gd-enhancing and new or enlarging T2 lesions on brain MRI scans</measure>
    <time_frame>At 12 months after the first dose of study drug</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ATA188</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Parts 1 and 2 will receive ATA188 intravenously as described in the Detailed Description.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in Part 2 will receive placebo matching to ATA188 intravenously as described in the Detailed Description (i.e., will receive placebo only in the first year, and thereafter will receive ATA188 for the remainder of the study).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATA188</intervention_name>
    <description>ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.</description>
    <arm_group_label>ATA188</arm_group_label>
    <other_name>Epstein-Barr Virus-directed cytotoxic T lymphocytes (CTLs)</other_name>
    <other_name>EBV-CTLs</other_name>
    <other_name>EBV-targeted T-cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to ATA188</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For Part 2: 18 to &lt; 61 years of age&#xD;
&#xD;
          -  For Part 2: Current diagnosis of a progressive form of MS as defined by the 2017&#xD;
             Revised McDonald criteria&#xD;
&#xD;
          -  For Part 2: EDSS scores of 3.0 to 6.5&#xD;
&#xD;
          -  Positive EBV serology&#xD;
&#xD;
          -  For Part 1 (recruitment completed): 18 to &lt; 66 years of age&#xD;
&#xD;
          -  For Part 1 (recruitment completed): History of progressive forms of MS as defined by&#xD;
             the 2010 Revised McDonald criteria for the diagnosis of MS&#xD;
&#xD;
          -  For Part 1 (recruitment completed): EDSS scores of 3.0 to 7.0&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical relapse as follows: For Part 2: Documented clinical and/or radiological&#xD;
             relapse for 2 years prior to screening, including gadolinium (Gd)-enhancing lesion(s)&#xD;
             on any brain MRI scans available during this period (A participant will also be&#xD;
             considered ineligible if any clinical and/or radiological relapse is reported between&#xD;
             screening and the first dose of study drug.); For Part 1 (recruitment completed):&#xD;
             Active clinical relapse between providing informed consent and the first dose of study&#xD;
             drug&#xD;
&#xD;
          -  Concurrent serious uncontrolled or unresolved medical condition&#xD;
&#xD;
          -  Positive serology and/or nucleic acid testing (NAT) for human immunodeficiency virus&#xD;
             (HIV), active hepatitis B virus (HBV) infection or carrier status for HBV, active&#xD;
             hepatitis C virus (HCV) infection&#xD;
&#xD;
          -  For Part 1: Positive serology for syphilis or human T cell lymphotrophic virus I/II&#xD;
&#xD;
          -  Clinically significant abnormalities of full blood count, renal function, or hepatic&#xD;
             function&#xD;
&#xD;
          -  Any contraindication to MRI and/or Gd, eg., any object that is reactive to strong&#xD;
             static magnetic, pulsed-gradient fields including any metallic fragments or foreign&#xD;
             body (eg, aneurysm clip[s], pacemakers, electronic implants, shunts)&#xD;
&#xD;
          -  Prior therapy with corticosteroids (within 2 weeks before Cycle 1 Day 1)&#xD;
&#xD;
          -  Prior therapy (30 days) B-cell depleting agent (eg, anti-CD20 agents such as&#xD;
             ocrelizumab); participant must be progressing despite therapy to be eligible&#xD;
&#xD;
          -  Prior therapy (6 half-lives or 30 days, whichever is longer) with glatiramer acetate,&#xD;
             interferon (IFN) Î², nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators (eg,&#xD;
             dimethyl fumarate ), methotrexate, azathioprine, cyclosporine, fingolimod,&#xD;
             natalizumab, teriflunomide, mitoxantrone, cyclophosphamide, any other&#xD;
             immunosuppressant or cytotoxic therapy (other than steroids), antithymocyte globulin&#xD;
             or similar anti-T cell antibody therapy, or any other investigational product for&#xD;
             Parts 1 and 2, and cladribine for Part 1 and IV immunoglobin, plasmapheresis, Bruton's&#xD;
             tyrosine kinase inhibitors, all sphingosine 1-phosphate receptor modulators for Part 2&#xD;
&#xD;
          -  Any previous treatment with alemtuzumab, stem cell transplant, or EBV T-cell therapy&#xD;
             for both parts and cladribine for Part 2&#xD;
&#xD;
          -  Unwilling to use protocol specified contraceptive methods&#xD;
&#xD;
          -  Women who are breastfeeding&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiren Kresa-Reahl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Atara Biotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>650-278-8930</phone>
    <phone_ext>option 1</phone_ext>
    <email>clinicalstudies@atarabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Steinman, MD</last_name>
      <phone>605-725-6401</phone>
      <email>steiny@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Cree, MD</last_name>
      <phone>415-514-2467</phone>
      <email>bruce.cree@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Alvarez, MD, PhD, MSCI</last_name>
      <phone>303-724-4644</phone>
      <email>NeurologyResearchPartners@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, PA-Maitland</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Honeycutt, MD, BS</last_name>
      <phone>407-647-5996</phone>
      <phone_ext>7</phone_ext>
      <email>neurologyassoc@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida, Morsani College of Medicine</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derrick Robertson, MD</last_name>
      <phone>813-974-3541</phone>
      <email>dsrobert@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The NeuroMedical Center Clinic, PC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70810-1685</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Bagert, MD</last_name>
      <phone>504-703-7458</phone>
      <email>bbagert@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center KUMC - Multiple Sclerosis MS Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Lynch, MD, BS</last_name>
      <phone>913-588-8198</phone>
      <email>SLYNCH@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Naismith, MD</last_name>
      <phone>314-362-2017</phone>
      <email>naismithr@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center-The Neurological Institute of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Riley, MD</last_name>
      <phone>212-305-6876</phone>
      <email>csr53@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Piedmont Healthcare</name>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <zip>28117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Dubois, MD</last_name>
      <phone>704-235-1834</phone>
      <email>Jessica.Barbour@accellacare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Bar-Or, MD, FRCP, FAAN, FANA</last_name>
      <phone>215-220-9384</phone>
      <email>amitbar@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Premier Neurology P.C.</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hughes, MD</last_name>
      <phone>608-848-8900</phone>
      <email>mhughes@premier-neuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Neurosciences Institute ANI - Franklin</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Hunter</last_name>
      <phone>615-791-5470</phone>
      <email>frontdesk@neurosci.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center VUMC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Moses, MD, BS</last_name>
      <phone>615-322-4085</phone>
      <email>katie.lyons@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lindsey, MD</last_name>
      <phone>832-325-7082</phone>
      <email>john.w.lindsey@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MS Center of Greater Washington</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <zip>22182</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Crayton, MD</last_name>
      <phone>703-226-4000</phone>
      <email>mymscenter@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inland Northwest Research LLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Aldred, MD</last_name>
      <phone>509-960-2818</phone>
      <email>jaldred@selkirkneurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Obeidat, MD</last_name>
      <phone>414-955-0690</phone>
      <email>aobeidat@mcw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Hodgkinson, BSc, MB, BSFRACP, PhD</last_name>
      <phone>+61(0) 2 96164689</phone>
      <email>s.hodgkinson@unsw.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zara Ioannides, MBBS, BSC, FRACP, Mphil</last_name>
      <phone>+61 (0) 7 3346 6022</phone>
      <email>z.ioannides@uq.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Griffith University, School of Medicine</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4222</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon J Broadley, BSc, MBChB, PhD, FRACP</last_name>
      <phone>+61 (0) 7 567 80174</phone>
      <email>simon.broadley@griffith.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Mult Scler. 2014 Oct;20(11):1541-4. doi: 10.1177/1352458514521888. Epub 2014 Feb 3.</citation>
    <PMID>24493474</PMID>
  </reference>
  <reference>
    <citation>Pender MP, Csurhes PA, Burrows JM, Burrows SR. Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clin Transl Immunology. 2017 Jan 20;6(1):e126. doi: 10.1038/cti.2016.87. eCollection 2017 Jan. Erratum in: Clin Transl Immunology. 2017 Jun 16;6(6):e147.</citation>
    <PMID>28197337</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 13, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2017</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis (MS)</keyword>
  <keyword>Primary Progressive Multiple Sclerosis</keyword>
  <keyword>Secondary Progressive Multiple Sclerosis</keyword>
  <keyword>Epstein-Barr Virus (EBV)</keyword>
  <keyword>EBV-associated Multiple Sclerosis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Central Nervous System</keyword>
  <keyword>Autoimmune Disease</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>Demyelination</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>T-cell</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>EBV viremia</keyword>
  <keyword>Off-the-shelf (T cells)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

